Sepracor-Looks very promising Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Ed Ajootian who wrote (3679)	9/8/1999 10:33:00 PM
From: Biomaven	Read Replies (2) of 10280

Ed, My feeling is that the proposed closing of the pooling window won't be quite the merger driver I once thought it would be. The reason is that the board has abandoned its additional proposal to force amortization of acquired R&D rather than allowing for an immediate write off of a big chunk of the goodwill. Further, and perhaps more important, the Board now allows a dual presentation of earnings, both with and without amortization of goodwill. Companies are increasingly taking advantage of this (our earnings were $1 before taking into account a charge of $0.30 stemming from our purchase of ...). That said, I agree that pooling is cleaner and there will be some pressure to get in ahead of the deadline (which isn't a definite date yet - the 12/2000 date is just an estimate). After I've read the Exposure Draft I'll post some comments about it on the Munch thread. My assumption on US royalties for Allegra is that they must be a fair bit lower than the original deal, which wasn't that generous to begin with. We also don't know exactly which non-US companies SEPR will be getting royalties from. I would assume that the non-US sales should climb fairly rapidly from here. Peter

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next